How Should Cytomegalovirus Infection Be Managed in Allogeneic Hematopoietic Stem Cell Transplant Recipients? A Clinical Grand Round. (PubMed, Infect Chemother) - Apr 4, 2025 - "During the foscarnet shortage, cidofovir was used, leading to a decline in CMV levels when foscarnet was reintroduced and used for 2 months. Following allo-HCT, CMV prophylaxis with letermovir is crucial to prevent reactivation in seropositive recipients...Maribavir is an option in cases of ganciclovir/valganciclovir resistance or intolerance. CMV gene mutations should be examined in patients with suspected resistance after 2 weeks of appropriate treatment. This case was discussed at the Clinical Grand Round of the Annual Conference of the Korean Society of Infectious Diseases on November 2, 2023."
Grand rounds • Journal • Review • Bone Marrow Transplantation • Cytomegalovirus Infection • Gene Therapies • Infectious Disease • Transplantation
|
|
Dong-Gun Lee; Dukhee Nho; Raeseok Lee; Sung-Yeon Cho
|